Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975284 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL11491429 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL968053 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL4975291 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL8838682 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL9547867 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL4975685 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A | |
| SCHEMBL11405856 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A | |
| SCHEMBL4975682 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A | |
| SCHEMBL11405854 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0624574-B1 | Novel prostaglandin analogue | MIZUSHIMA YUTAKA (JP) | 1999-04-21 | — | — | EP | claimed |
| EP-0624574-A2 | Novel prostaglandin analogue | MIZUSHIMA, Yutaka (JP) | 1994-11-17 | — | — | EP | claimed |
| EP-2864308-B1 | (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues | UNIV BRISTOL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150158837-A1 | Compound And Method | TOPOKINE THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-7872045-B2 | Treating ocular hypertension, glaucoma, by administering prostaglandin derivatives such as {3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-(hydroxy)-5-(naphthyl)pent-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid methyl ester | ALLERGAN, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1395263-B1 | 3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7473704-B2 | Cyclohexyl prostaglandin analogs as EP4-receptor agonists | ALLERGAN, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1085012-B1 | PROCESS FOR PRODUCING A PURIFIED PROSTAGLANDIN DERIVATIVE | ASAHI GLASS CO LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-7429615-B2 | Cyclohexyl prostaglandin analogs as EP4-receptor agonists | ALLERGAN, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1385526-B1 | 3, 7 THIA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-0423697-B1 | Emulsion of lipid containing a prostaglandin analogue | MIZUSHIMA YUTAKA (JP) | 1995-02-01 | — | — | EP | disclosed |
| EP-0624574-A2 | Novel prostaglandin analogue | MIZUSHIMA, Yutaka (JP) | 1994-11-17 | — | — | EP | disclosed |
| US-5120870-A | Oil-in-water type; storage stability, heat resistance, drug delivery | Mizushima, Yutaka (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0423697-A2 | Emulsion of lipid containing a prostaglandin analogue | MIZUSHIMA, Yutaka (JP) | 1991-04-24 | — | — | EP | disclosed |
| US-4906663-A | 6-fluoroprostaglandins | ASAHI GLASS COMPANY, LTD. (JP) | 1990-03-06 | — | — | US | disclosed |
| EP-0312055-A2 | 6-Fluoroprostaglandins | ASAHI GLASS COMPANY LTD. (JP) | 1989-04-19 | — | — | EP | disclosed |
| EP-0102230-B1 | NOVEL 6-NITROPROSTAGLANDIN DERIVATIVES, PROCESS FOR PRODUCTION THEREOF, AND USE THEREOF | TEIJIN LIMITED (JP) | 1987-04-29 | — | — | EP | disclosed |
| EP-0112633-A2 | Novel 5-thiaprostaglandin, process for production thereof, and pharmaceutical use thereof | TEIJIN LIMITED (JP) | 1984-07-04 | — | — | EP | disclosed |
| US-4180672-A | 2-Organothio-2-cyclopentenones, organothio-cyclopentanes derived therefrom | TEIJIN LIMITED (JP) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158837-A1 | Compound And Method | CYP4A11, NR1H2, NR1H3 | CA2 3363/4885MEN1 2871/4885KMT2A 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.